Eyelid masses: a 10-year survey from a tertiary eye hospital in Tehran

The purpose of this study was to evaluate the demographics and clinical features of eyelid masses in a tertiary eye hospital over a 10-year period. A retrospective chart review was performed for patients admitted with eyelid tumors from 2000 to 2010. Data were collected and analyzed on the demographic features, location of the tumor, types of treatment, and pathologic findings. A total number of 182 patients were evaluated of which, 82 cases were benign and 100 cases were malignant neoplasms. The most common benign tumors included melanocytic nevi [35%], papilloma [19.5%], and cysts [11%]. The most frequent malignant tumors included basal cell carcinoma [BCC] [83%], squamous cell carcinoma [8%] and sebaceous gland carcinoma [6%]. The most common site for malignancy was the lower lid followed by the upper lid. BCC recurred in 16 cases that were most frequent in the lower lid. Melanocytic nevus, papilloma and cysts are the most common benign lesions and BCC is the most common malignant lesion in the eyelids. Recurrence is a feature of BCC especially in the lower lid

OPTIMA tacrolimus-eluting stent: a twelve-month clinical follow up with two different periods of dual antiplatelet therapy; 2-monthvs. 6-month approach

There are limited data comparing long-term efficacy and safety of OPTIMA tacrolimus-eluting stent [TES] with Dual Antiplatelet Therapy [DAT] in daily practice. Therefore, we evaluated the safety and performance of OPTIMA TES with 2 or 6-month dual antiplatelet therapy in a 12-month follow up period. In a prospective, non-randomized single center registry in which 106 patients that underwent percutaneous coronary intervention with the OPTIMA TES between January 2010 and February 2011 were enrolled. After stenting, 62 patients received DAT for 2 months and the remainder for 6 months. Major Adverse Cardiac Events [MACE], stent thrombosis rate and target lesion revascularization [TLR] were evaluated in a 12-month follow-up period for 2-and 6-month DAT groups. No cases with death, MI or stent thrombosis were observed within the 12-month follow-up period in either of the groups. TLR and MACE rates were higher in 6-month DAT group compared to 2-month group [6.8% vs. 3.2% respectively, P=0.001] which may be due to this group having more diffuse disease [23.60 +/- 5.69 vs. 20.88 +/- 5.14, P=0.018]. OPTIMA tacrolimus-eluting stent is safe and efficient with short term DAT period. A randomized trial is needed for better evaluations of OPTIMA TES in daily clinical practice.